{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "30",
                "@year": "2023",
                "@timestamp": "2023-06-30T02:47:28.000028-04:00",
                "@month": "06"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2021",
                "@month": "10"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": [
                {"xocs:funding-agency-matched-string": "Bayer Health Pharma"},
                {"xocs:funding-agency-matched-string": "CytomX"},
                {"xocs:funding-agency-matched-string": "Falk"},
                {"xocs:funding-agency-matched-string": "Halozyme Pharmaceuticals"},
                {"xocs:funding-agency-matched-string": "Incyte"},
                {"xocs:funding-agency-matched-string": "QED Therapeutics"},
                {"xocs:funding-agency-matched-string": "Senhwa Pharmaceuticals"},
                {"xocs:funding-agency-matched-string": "Shire Baxalta"},
                {
                    "xocs:funding-agency-matched-string": "Bristol Myers Squibb",
                    "xocs:funding-agency-acronym": "BMS",
                    "xocs:funding-agency": "Bristol-Myers Squibb",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100002491",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "AstraZeneca",
                    "xocs:funding-agency": "AstraZeneca",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004325",
                    "xocs:funding-agency-country": "http://sws.geonames.org/2635167/"
                },
                {
                    "xocs:funding-agency-matched-string": "Genentech",
                    "xocs:funding-agency": "Genentech",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004328",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Merck",
                    "xocs:funding-agency": "Merck",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004334",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Novartis",
                    "xocs:funding-agency": "Novartis",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004336",
                    "xocs:funding-agency-country": "http://sws.geonames.org/2658434/"
                },
                {
                    "xocs:funding-agency-matched-string": "Roche",
                    "xocs:funding-agency": "Roche",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004337",
                    "xocs:funding-agency-country": "http://sws.geonames.org/2658434/"
                },
                {
                    "xocs:funding-agency-matched-string": "Gilead",
                    "xocs:funding-agency": "Gilead Sciences",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100005564",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Celgene",
                    "xocs:funding-agency": "Celgene",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100006436",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Novartis",
                    "xocs:funding-agency-acronym": "NPC",
                    "xocs:funding-agency": "Novartis Pharmaceuticals Corporation",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100008272",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Exelixis",
                    "xocs:funding-agency": "Exelixis",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100010544",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "G1 Therapeutics",
                    "xocs:funding-agency": "TG Therapeutics",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100013252",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Ipsen",
                    "xocs:funding-agency": "Ipsen Biopharmaceuticals",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100013733",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Eisai",
                    "xocs:funding-agency": "Eisai",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/501100003769",
                    "xocs:funding-agency-country": "http://sws.geonames.org/1861060/"
                },
                {
                    "xocs:funding-agency-matched-string": "Servier",
                    "xocs:funding-agency": "Servier",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/501100011725",
                    "xocs:funding-agency-country": "http://sws.geonames.org/3017382/"
                }
            ],
            "xocs:funding-addon-generated-timestamp": "2022-11-15T10:12:56.812Z",
            "xocs:funding-text": [
                {"$": "MJ reports medical writing support from QED Therapeutics; grants from QED Therapeutics, Incyte, Taiho, Basilea, OncoSil, Meclun, Agios, AstraZeneca, and Merck; consulting fees from QED Therapeutics, Incyte, Taiho, Basilea, Oncosil, Meclun, Agios, and AstraZeneca; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from QED Therapeutics, Incyte, Taiho, Basilea, Oncosil, Meclun, Agios, AstraZeneca, and EMD Serono; and participation on a data safety monitoring board or advisory board for NuCana, QED Therapeutics, Incyte, Taiho, Basilea, Oncosil, Meclun, Agios, and AstraZeneca. SR reports clinical trial financial support to their institution from QED Therapeutics; consulting fees from QED Therapeutics and Merck; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from IDT Integrated DNA Technologies and Illumina; financial support for attending meetings or travel from Incyte; and participation on a data safety monitoring board or advisory board for Incyte, AbbVie, QED Therapeutics, and Bayer. RKK reports funding (to their institution), supply of the study drug, medical writing support, and payment of article processing charges from QED Therapeutics; research financial support for conduct of clinical trials (to their institution) from Agios, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly, EMD Serono, Exelixis, Genentech, Merck, Novartis, Partner Therapeutics, QED Therapeutics, and Taiho; support for travel to a 2019 presentation at a satellite symposium from Ipsen; membership of independent data safety monitoring committees or data and safety monitoring boards for Genentech/Roche and Merck (compensation to self from Genentech/Roche in 2018\u201319; other independent data safety monitoring committee roles uncompensated); advisory board payments to self from Gilead, Exact Sciences, and Genentech; and advisory board payments to institution from Agios, AstraZeneca, Bristol Myers Squibb, and Merck. SS reports research funding to their institution from QED Therapeutics, Boehringer Ingelheim, and Zymeworks; consulting fees from QED Therapeutics, Eisai, and Exelixis; and honoraria for lectures, presentations, or speaker bureau from QED Therapeutics, Lilly, Eisai, and Exelexis. KHW reports consulting fees from Alexion, Bayer, Eisai, Novartis, Orphalan, Pfizer, Vivit therapeutics, Ultragenyx, and Univar, and travel support from Gilead. D-TW works for the speaker bureau of or gives expert testimony for AstraZeneca, Eisai, Bristol Myers Squibb, Celgene, Incyte, Ipsen, Falk, Novartis, Roche Pharma AG, Servier, Shire Baxalta, and Sirtex; reports financial support with travel, accommodation, and expenses from Bayer Health Pharma, Celgene, Novartis, and Sirtex; and has submitted a research grant application to Servier (to institution). LG reports research funding to their institution from Agios, Adaptimmune, Bayer, Eisai, Merck, MacroGenics, Genentech, Novartis, Incyte, Loxo Oncology, Relay Therapeutics, QED Therapeutics, Taiho Oncology, Leap Therapeutics, Bristol Myers Squibb, and NuCana; scientific advisory board fees (to self) from Agios Pharmaceuticals, Alentis Therapeutics AG, H3 Biomedicine, Incyte, QED Therapeutics, Sirtex Medical, and Taiho Oncology; consulting fees (to self) from Agios Pharmaceuticals, Alentis Therapeutics, Genentech, Exelixis, Incyte Corporation, QED Therapeutics, Sirtex Medical, and Taiho Oncology; and participation in an independent data safety monitoring committee for AstraZeneca. IB reports research scientific advisory board fees (to self) from QED Therapeutics, Servier, and Taiho Oncology; consulting fees (to self) from Roche and QED Therapeutics; and financial support for conduct of clinical trials (to their institution) from Servier. AE-K reports medical writing support from QED Therapeutics; grants to their institution from AstraZeneca, Astex, and Fulgent; and consulting fees from Agenus, Bristol Myers Squibb, Merck, Roche-Genentech, EISAI, Exelixis, QED Therapeutics, Gilead, AstraZeneca, ABL Bio, CytomX, and Pieris; MJB reports financial support (to their institution) from QED Therapeutics; grants to their institution from Senhwa Pharmaceuticals, Adaptimmune, Agios Pharmaceuticals, Halozyme Pharmaceuticals, Celgene Pharmaceuticals, EMD Merck Serono, Toray, Dicerna, Taiho Pharmaceuticals, Sun Biopharma, Isis Pharmaceuticals, RedHill Pharmaceuticals, Boston Biomed, Basilea, Incyte Pharmaceuticals, Mirna Pharmaceuticals, Medimmune, Bioline, SillaJen, ARIAD Pharmaceuticals, Puma Biotechnology, and Novartis Pharmaceuticals; and consulting fees from ADC Therapeutics, Exelexis, Inspyr Therapeutics, G1 Therapeutics, Immunovative Therapies, OncBioMune Pharma, Western Oncolytics, Lynx Group, Genentech, Merck, and Huya. WPY reports receiving an honorarium fee (to self) from Taiho; fees (to self) for consulting or advisory roles from Bristol Myers Squibb, Eisai, Ipsen, MSD, and Novartis; and royalties (to self) from miRXES. PAP reports grants and consulting fees from QED Therapeutics. MB reports a one-time advisory board payment from Incyte Biosciences Germany. AL has been employed at QED Therapeutics since August, 2018, and has stock or stock options in BridgeBio. AP has been a full-time employee of QED Therapeutics since Oct 15, 2019, and has stock in BridgeBio. HSS has been a full-time employee of QED Therapeutics since November, 2018, and has stock and stock options in BridgeBio. SPS is a full-time employee of QED Therapeutics; has a patent planned, issued, or pending for Corcept and AbbVie; and has stock or stock options in BridgeBio, Abbott, AbbVie, Johnson & Johnson, Corcept, and Calithera Biosciences. SM is a full-time employee of QED Therapeutics; has a patent planned, issued, or pending (PCT/US20/34881: methods of treating cholangiocarcinoma); and stock or stock options in BridgeBio. AXZ reports consulting fees from Lilly, Eisai, Bayer, Merck, Sanofi, Roche, and Exelixis. TSB-S reports research funding (to institution) from Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Amgen, Merck, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, and Bristol Myers Squibb; consulting fees (to institution) from Ipsen, Arcus, Array Biopharma, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, and Merck; consulting fees (to self) from AbbVie, Boehringer Ingelheim, Janssen, Eisai, Daichii Sankyo, Natera, TreosBio, Celularity, Exact Science, Sobi, Beigene, Kanaph, Xilis, AstraZeneca, and Foundation Medicine; fees for independent data monitoring committees and drug and safety monitoring boards (to self) from AstraZeneca, Exelixis, Lilly, PanCan, and 1Globe; fees for participating in scientific advisory boards for Imugene, Immuneering, and Sun Biopharma; and inventions or patents WO/2018/183488 and WO/2019/055687. GKA-A reports medical writing support for the present manuscript from QED Therapeutics; grants from Arcus, Agios, AstraZeneca, Bayer, BioNtech, Bristol Myers Squibb, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, SillaJen, and Yiviva; consulting fees from Agios, AstraZeneca, Alnylam, Autem, Bayer, BeiGene, Berry Genomics, Celgene, CytomX, Eisai, Eli Lilly, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte, Ipsen, Legend Biotech, Loxo, Merck, MiNA, QED Therapeutics, RedHill, Rafael, Silenseed, SillaJen, Sobi, Surface Oncology, TheraBionic, twoXAR, Vector, and Yiviva; and patents planned, issued, or pending for articles and methods for preventing and treating dermatological adverse events (identified by the International Patent Application number PCT/US2014/031545, filed on March 24, 2014, and with the priority application serial number 61/804,907, filed on March 25, 2013). All other authors declare no competing interests."},
                {"$": "This study was funded by Novartis and QED Therapeutics, an affiliate of BridgeBio, and was presented, in part, at the 2020 Cholangiocarcinoma Foundation Annual Conference (July 22\u201324, 2020) and at the 2021 Gastrointestinal Cancers Symposium (Jan 15\u201317, 2021). We thank all patients who participated in this study, the patients' families, the clinical investigators, the clinical research nurses, the clinical research monitors, the data management team, and all other members of the 2204 clinical study team. We also thank Roo Vold at QED Therapeutics for helping with data verification and editorial review, and Lee Miller and Deirdre Carman at Miller Medical Communications for their medical editing and writing assistance, which was funded by QED Therapeutics."},
                {"$": "This study was funded by Novartis and QED Therapeutics, an affiliate of BridgeBio, and was presented, in part, at the 2020 Cholangiocarcinoma Foundation Annual Conference (July 22\u201324, 2020) and at the 2021 Gastrointestinal Cancers Symposium (Jan 15\u201317, 2021). We thank all patients who participated in this study, the patients' families, the clinical investigators, the clinical research nurses, the clinical research monitors, the data management team, and all other members of the 2204 clinical study team. We also thank Roo Vold at QED Therapeutics for helping with data verification and editorial review, and Lee Miller and Deirdre Carman at Miller Medical Communications for their medical editing and writing assistance, which was funded by QED Therapeutics."}
            ],
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60015023",
                            "@country": "usa",
                            "city": "Houston",
                            "organization": [
                                {"$": "Department of Gastrointestinal Medical Oncology"},
                                {"$": "MD Anderson Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60015023",
                                "@dptid": "103772879"
                            },
                            "state": "TX",
                            "@affiliation-instance-id": "S2468125321001965-22ecca0241b52f4ee139007d440cb353",
                            "ce:source-text": "Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA",
                            "@dptid": "103772879"
                        },
                        "author": [{
                            "ce:given-name": "Milind",
                            "preferred-name": {
                                "ce:given-name": "Milind",
                                "ce:initials": "M.",
                                "ce:surname": "Javle",
                                "ce:indexed-name": "Javle M."
                            },
                            "@seq": "1",
                            "@author-instance-id": "S2468125321001965-74be6a2dff1a7d37b0ee1e604e691ec4",
                            "ce:initials": "M.",
                            "@date-locked": "2022-02-24T17:29:44.710",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Javle",
                            "@auid": "35425978300",
                            "ce:indexed-name": "Javle M."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60002058",
                            "@country": "usa",
                            "city": "Columbus",
                            "organization": [
                                {"$": "James Cancer Hospital"},
                                {"$": "Ohio State University Comprehensive Cancer Center"}
                            ],
                            "affiliation-id": {"@afid": "60002058"},
                            "state": "OH",
                            "@affiliation-instance-id": "S2468125321001965-0de5bcca977563c3d923130c9900170b",
                            "ce:source-text": "James Cancer Hospital, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA"
                        },
                        "author": [{
                            "ce:given-name": "Sameek",
                            "preferred-name": {
                                "ce:given-name": "Sameek",
                                "ce:initials": "S.",
                                "ce:surname": "Roychowdhury",
                                "ce:indexed-name": "Roychowdhury S."
                            },
                            "@seq": "2",
                            "@author-instance-id": "S2468125321001965-efafb6df9992ddbd866861692d05433d",
                            "ce:initials": "S.",
                            "@date-locked": "2022-03-03T02:39:56.568",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Roychowdhury",
                            "@auid": "7005297383",
                            "ce:indexed-name": "Roychowdhury S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60002058",
                            "@country": "usa",
                            "city": "Columbus",
                            "organization": [
                                {"$": "Department of Internal Medicine"},
                                {"$": "Ohio State University Comprehensive Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60002058",
                                "@dptid": "112776723"
                            },
                            "state": "OH",
                            "@affiliation-instance-id": "S2468125321001965-7b3767a9de0474e843124e64b705e7e9",
                            "ce:source-text": "Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA",
                            "@dptid": "112776723"
                        },
                        "author": [{
                            "ce:given-name": "Sameek",
                            "preferred-name": {
                                "ce:given-name": "Sameek",
                                "ce:initials": "S.",
                                "ce:surname": "Roychowdhury",
                                "ce:indexed-name": "Roychowdhury S."
                            },
                            "@seq": "2",
                            "@author-instance-id": "S2468125321001965-efafb6df9992ddbd866861692d05433d",
                            "ce:initials": "S.",
                            "@date-locked": "2022-03-03T02:39:56.568",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Roychowdhury",
                            "@auid": "7005297383",
                            "ce:indexed-name": "Roychowdhury S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60029881",
                            "@country": "usa",
                            "city": "San Francisco",
                            "organization": [
                                {"$": "Department of Medicine"},
                                {"$": "Division of Hematology/Oncology"},
                                {"$": "UCSF Helen Diller Family Comprehensive Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60029881",
                                "@dptid": "104512050"
                            },
                            "state": "CA",
                            "@affiliation-instance-id": "S2468125321001965-1f325c891dc5970254e8f3799d715442",
                            "ce:source-text": "Department of Medicine, Division of Hematology/Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA",
                            "@dptid": "104512050"
                        },
                        "author": [{
                            "ce:given-name": "Robin Kate",
                            "preferred-name": {
                                "ce:given-name": "Robin Kate",
                                "ce:initials": "R.K.",
                                "ce:surname": "Kelley",
                                "ce:indexed-name": "Kelley R.K."
                            },
                            "@seq": "3",
                            "@author-instance-id": "S2468125321001965-e6853a9d2e65a0dbc770544b0688b10d",
                            "ce:initials": "R.K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Kelley",
                            "@auid": "17635112900",
                            "ce:indexed-name": "Kelley R.K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60005247",
                            "@country": "usa",
                            "city": "Los Angeles",
                            "organization": [
                                {"$": "Division of Hematology and Oncology"},
                                {"$": "David Geffen School of Medicine at UCLA"}
                            ],
                            "affiliation-id": {
                                "@afid": "60005247",
                                "@dptid": "112835032"
                            },
                            "state": "CA",
                            "@affiliation-instance-id": "S2468125321001965-8850ff7c399bdf82a43faac6a6364131",
                            "ce:source-text": "Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA",
                            "@dptid": "112835032"
                        },
                        "author": [{
                            "ce:given-name": "Saeed",
                            "preferred-name": {
                                "ce:given-name": "Saeed",
                                "ce:initials": "S.",
                                "ce:surname": "Sadeghi",
                                "ce:indexed-name": "Sadeghi S."
                            },
                            "@seq": "4",
                            "@author-instance-id": "S2468125321001965-8a7959ae218398813518b8e515aa86b6",
                            "ce:initials": "S.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Sadeghi",
                            "@auid": "7006682027",
                            "ce:indexed-name": "Sadeghi S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Spain",
                            "@afid": "60012486",
                            "@country": "esp",
                            "city": "Barcelona",
                            "organization": [
                                {"$": "Department of Medical Oncology"},
                                {"$": "Hospital Vall d'Hebron"}
                            ],
                            "affiliation-id": {
                                "@afid": "60012486",
                                "@dptid": "113409408"
                            },
                            "@affiliation-instance-id": "S2468125321001965-259d21f56aab69b883a8ce35fe228069",
                            "ce:source-text": "Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain",
                            "@dptid": "113409408"
                        },
                        "author": [{
                            "ce:given-name": "Teresa",
                            "preferred-name": {
                                "ce:given-name": "Teresa",
                                "ce:initials": "T.",
                                "ce:surname": "Macarulla",
                                "ce:indexed-name": "Macarulla T."
                            },
                            "@seq": "5",
                            "@author-instance-id": "S2468125321001965-a8d9d1c7bf7bb065db7727afda84833c",
                            "ce:initials": "T.",
                            "@date-locked": "2021-12-30T13:27:33.195",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Macarulla",
                            "@auid": "8702260000",
                            "ce:indexed-name": "Macarulla T."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Germany",
                            "@afid": "60082880",
                            "@country": "deu",
                            "city": "Heidelberg",
                            "organization": [
                                {"$": "Internal Medicine"},
                                {"$": "Salem Medical Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60082880",
                                "@dptid": "105978225"
                            },
                            "@affiliation-instance-id": "S2468125321001965-d00521ff658548e52a0064f83cc4656d",
                            "ce:source-text": "Internal Medicine, Salem Medical Center, Heidelberg, Germany",
                            "@dptid": "105978225"
                        },
                        "author": [{
                            "ce:given-name": "Karl Heinz",
                            "preferred-name": {
                                "ce:given-name": "Karl Heinz",
                                "ce:initials": "K.H.",
                                "ce:surname": "Weiss",
                                "ce:indexed-name": "Weiss K.H."
                            },
                            "@seq": "6",
                            "@author-instance-id": "S2468125321001965-8c770b2d45e3341403e1d161c4b1997c",
                            "ce:initials": "K.H.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Weiss",
                            "@auid": "13204330300",
                            "ce:indexed-name": "Weiss K.H."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Germany",
                            "@afid": "60003280",
                            "@country": "deu",
                            "city": "Heidelberg",
                            "organization": [
                                {"$": "Internal Medicine IV"},
                                {"$": "University Hospital Heidelberg"}
                            ],
                            "affiliation-id": {
                                "@afid": "60003280",
                                "@dptid": "103217730"
                            },
                            "@affiliation-instance-id": "S2468125321001965-b1c9211e8f5ae463f414ab706339f6fa",
                            "ce:source-text": "Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany",
                            "@dptid": "103217730"
                        },
                        "author": [{
                            "ce:given-name": "Karl Heinz",
                            "preferred-name": {
                                "ce:given-name": "Karl Heinz",
                                "ce:initials": "K.H.",
                                "ce:surname": "Weiss",
                                "ce:indexed-name": "Weiss K.H."
                            },
                            "@seq": "6",
                            "@author-instance-id": "S2468125321001965-8c770b2d45e3341403e1d161c4b1997c",
                            "ce:initials": "K.H.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Weiss",
                            "@auid": "13204330300",
                            "ce:indexed-name": "Weiss K.H."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Germany",
                            "@afid": "60008658",
                            "@country": "deu",
                            "city": "Cologne",
                            "organization": [
                                {"$": "Clinic for Gastroenterologie and Hepatologie"},
                                {"$": "Klinikum der Universität zu Köln"}
                            ],
                            "affiliation-id": {
                                "@afid": "60008658",
                                "@dptid": "127082506"
                            },
                            "@affiliation-instance-id": "S2468125321001965-d9e8937000309833ad3611d132c96b95",
                            "ce:source-text": "Clinic for Gastroenterologie and Hepatologie, Klinikum der Universität zu Köln, Cologne, Germany",
                            "@dptid": "127082506"
                        },
                        "author": [{
                            "ce:given-name": "Dirk-Thomas",
                            "preferred-name": {
                                "ce:given-name": "Dirk Thomas",
                                "ce:initials": "D.T.",
                                "ce:surname": "Waldschmidt",
                                "ce:indexed-name": "Waldschmidt D.T."
                            },
                            "@seq": "7",
                            "@author-instance-id": "S2468125321001965-455b9c470aefee5590db119cef85100e",
                            "ce:initials": "D.-T.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Waldschmidt",
                            "@auid": "6505951794",
                            "ce:indexed-name": "Waldschmidt D.-T."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60008130",
                            "@country": "usa",
                            "city": "Boston",
                            "organization": [
                                {"$": "Hematology/Oncology"},
                                {"$": "Massachusetts General Hospital Cancer Center"}
                            ],
                            "affiliation-id": {"@afid": "60008130"},
                            "state": "MA",
                            "@affiliation-instance-id": "S2468125321001965-2fef53d186a0b0d6b99276309c2ed2a4",
                            "ce:source-text": "Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA"
                        },
                        "author": [{
                            "ce:given-name": "Lipika",
                            "preferred-name": {
                                "ce:given-name": "Lipika",
                                "ce:initials": "L.",
                                "ce:surname": "Goyal",
                                "ce:indexed-name": "Goyal L."
                            },
                            "@seq": "8",
                            "@author-instance-id": "S2468125321001965-04caab18f555f608d761c2f18f52e0bd",
                            "ce:initials": "L.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Goyal",
                            "@auid": "57216596420",
                            "ce:indexed-name": "Goyal L."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60008130",
                            "@country": "usa",
                            "city": "Boston",
                            "organization": [
                                {"$": "Medicine"},
                                {"$": "Massachusetts General Hospital Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60008130",
                                "@dptid": "117303679"
                            },
                            "state": "MA",
                            "@affiliation-instance-id": "S2468125321001965-fd032d05b0f96b34151f066692a68ef0",
                            "ce:source-text": "Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA",
                            "@dptid": "117303679"
                        },
                        "author": [{
                            "ce:given-name": "Andrew X",
                            "preferred-name": {
                                "ce:given-name": "Andrew X.",
                                "ce:initials": "A.X.",
                                "ce:surname": "Zhu",
                                "ce:indexed-name": "Zhu A.X."
                            },
                            "@seq": "21",
                            "@author-instance-id": "S2468125321001965-d92fc9cf6e16037f6e22a047e774f8d2",
                            "ce:initials": "A.X.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Zhu",
                            "@auid": "57216593782",
                            "ce:indexed-name": "Zhu A.X."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Belgium",
                            "@afid": "60012936",
                            "@country": "bel",
                            "city": "Brussels",
                            "organization": [
                                {"$": "Department of Hepato-gastroenterology"},
                                {"$": "Cliniques Universitaires St Luc"}
                            ],
                            "affiliation-id": {
                                "@afid": "60012936",
                                "@dptid": "103682248"
                            },
                            "@affiliation-instance-id": "S2468125321001965-09fed3ccb5ae9d8865024f9d916b4756",
                            "ce:source-text": "Department of Hepato-gastroenterology, Cliniques Universitaires St Luc, Brussels, Belgium",
                            "@dptid": "103682248"
                        },
                        "author": [{
                            "ce:given-name": "Ivan",
                            "preferred-name": {
                                "ce:given-name": "Ivan",
                                "ce:initials": "I.",
                                "ce:surname": "Borbath",
                                "ce:indexed-name": "Borbath I."
                            },
                            "@seq": "9",
                            "@author-instance-id": "S2468125321001965-5a9a2c13a306075ab40885aae8563424",
                            "ce:initials": "I.",
                            "@date-locked": "2022-09-22T02:05:44.792",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Borbath",
                            "@auid": "8986695600",
                            "ce:indexed-name": "Borbath I."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60022143",
                            "@country": "usa",
                            "city": "Los Angeles",
                            "organization": [
                                {"$": "Division of Medical Oncology"},
                                {"$": "USC Norris Comprehensive Cancer Center"},
                                {"$": "Keck School of Medicine"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60022143",
                                    "@dptid": "113678341"
                                },
                                {"@afid": "60015183"}
                            ],
                            "state": "CA",
                            "@affiliation-instance-id": "S2468125321001965-27ddb02d723b7acc7313914a6a1081d6",
                            "ce:source-text": "Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA",
                            "@dptid": "113678341"
                        },
                        "author": [{
                            "ce:given-name": "Anthony",
                            "preferred-name": {
                                "ce:given-name": "Anthony",
                                "ce:initials": "A.",
                                "ce:surname": "El-Khoueiry",
                                "ce:indexed-name": "El-Khoueiry A."
                            },
                            "@seq": "10",
                            "@author-instance-id": "S2468125321001965-8fc502f7b8e8d23c16f896c7331541fa",
                            "ce:initials": "A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "El-Khoueiry",
                            "@auid": "12244686400",
                            "ce:indexed-name": "El-Khoueiry A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60026952",
                            "@country": "usa",
                            "city": "Scottsdale",
                            "organization": [
                                {"$": "Department of Medical Oncology and Hematology"},
                                {"$": "Mayo Clinic"}
                            ],
                            "affiliation-id": {
                                "@afid": "60026952",
                                "@dptid": "104365850"
                            },
                            "state": "AZ",
                            "@affiliation-instance-id": "S2468125321001965-c9292fc4ae5b8dafeb41618364b374fb",
                            "ce:source-text": "Department of Medical Oncology and Hematology, Mayo Clinic, Scottsdale, AZ, USA",
                            "@dptid": "104365850"
                        },
                        "author": [{
                            "ce:given-name": "Tanios S",
                            "preferred-name": {
                                "ce:given-name": "Tanios S.",
                                "ce:initials": "T.S.",
                                "ce:surname": "Bekaii-Saab",
                                "ce:indexed-name": "Bekaii-Saab T.S."
                            },
                            "@seq": "22",
                            "@author-instance-id": "S2468125321001965-618dcc0f4eb967fc2e6bbb0624f6ffed",
                            "ce:initials": "T.S.",
                            "@date-locked": "2022-01-01T18:37:57.675",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Bekaii-Saab",
                            "@auid": "8643412400",
                            "ce:indexed-name": "Bekaii-Saab T.S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60026952",
                            "@country": "usa",
                            "city": "Scottsdale",
                            "organization": [
                                {"$": "Department of Internal Medicine"},
                                {"$": "Mayo Clinic"}
                            ],
                            "affiliation-id": {
                                "@afid": "60026952",
                                "@dptid": "100288422"
                            },
                            "state": "AZ",
                            "@affiliation-instance-id": "S2468125321001965-99c8ab92733b152f04d1c17bfff5d7b0",
                            "ce:source-text": "Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA",
                            "@dptid": "100288422"
                        },
                        "author": [{
                            "ce:given-name": "Mitesh J",
                            "preferred-name": {
                                "ce:given-name": "Mitesh J.",
                                "ce:initials": "M.J.",
                                "ce:surname": "Borad",
                                "ce:indexed-name": "Borad M.J."
                            },
                            "@seq": "11",
                            "@author-instance-id": "S2468125321001965-d2bfcb146f29262d64d5b9a8955e66b1",
                            "ce:initials": "M.J.",
                            "@date-locked": "2022-01-01T18:37:57.675",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Borad",
                            "@auid": "57202377479",
                            "ce:indexed-name": "Borad M.J."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Singapore",
                            "@afid": "60106366",
                            "@country": "sgp",
                            "organization": [
                                {"$": "National University Cancer Institute Singapore"},
                                {"$": "National University Health System"}
                            ],
                            "affiliation-id": {"@afid": "60106366"},
                            "@affiliation-instance-id": "S2468125321001965-326d4f1193bc3105cfb95c698280bc49",
                            "ce:source-text": "National University Cancer Institute Singapore, National University Health System, Singapore"
                        },
                        "author": [{
                            "ce:given-name": "Wei Peng",
                            "preferred-name": {
                                "ce:given-name": "Wei Peng",
                                "ce:initials": "W.P.",
                                "ce:surname": "Yong",
                                "ce:indexed-name": "Yong W.P."
                            },
                            "@seq": "12",
                            "@author-instance-id": "S2468125321001965-ae63118ceb65d22322452fa68be8d169",
                            "ce:initials": "W.P.",
                            "@date-locked": "2022-10-10T06:06:06.673",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MBChB",
                            "ce:surname": "Yong",
                            "@auid": "8928141300",
                            "ce:indexed-name": "Yong W.P."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Singapore",
                            "@afid": "60106362",
                            "@country": "sgp",
                            "organization": [
                                {"$": "Cancer Science Institute of Singapore"},
                                {"$": "National University of Singapore"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60106362"},
                                {"@afid": "60017161"}
                            ],
                            "@affiliation-instance-id": "S2468125321001965-72cd1e5d5a80972d1c0a7af2365ac618",
                            "ce:source-text": "Cancer Science Institute of Singapore, National University of Singapore, Singapore"
                        },
                        "author": [{
                            "ce:given-name": "Wei Peng",
                            "preferred-name": {
                                "ce:given-name": "Wei Peng",
                                "ce:initials": "W.P.",
                                "ce:surname": "Yong",
                                "ce:indexed-name": "Yong W.P."
                            },
                            "@seq": "12",
                            "@author-instance-id": "S2468125321001965-ae63118ceb65d22322452fa68be8d169",
                            "ce:initials": "W.P.",
                            "@date-locked": "2022-10-10T06:06:06.673",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MBChB",
                            "ce:surname": "Yong",
                            "@auid": "8928141300",
                            "ce:indexed-name": "Yong W.P."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60033199",
                            "@country": "usa",
                            "city": "Detroit",
                            "organization": {"$": "Karmanos Cancer Institute"},
                            "affiliation-id": {"@afid": "60033199"},
                            "state": "MI",
                            "@affiliation-instance-id": "S2468125321001965-4021f85d58ea79a54b682d6ac5fdff34",
                            "ce:source-text": "Karmanos Cancer Institute, Detroit, MI, USA"
                        },
                        "author": [{
                            "ce:given-name": "Philip A",
                            "preferred-name": {
                                "ce:given-name": "Philip A.",
                                "ce:initials": "P.A.",
                                "ce:surname": "Philip",
                                "ce:indexed-name": "Philip P.A."
                            },
                            "@seq": "13",
                            "@author-instance-id": "S2468125321001965-5b5dd83c38561df6a0d3403e7415d2f0",
                            "ce:initials": "P.A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Philip",
                            "@auid": "7102577497",
                            "ce:indexed-name": "Philip P.A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Germany",
                            "@afid": "60017246",
                            "@country": "deu",
                            "city": "Tübingen",
                            "organization": [
                                {"$": "Department of Internal Medicine I"},
                                {"$": "Eberhard-Karls University"}
                            ],
                            "affiliation-id": {
                                "@afid": "60017246",
                                "@dptid": "112670307"
                            },
                            "@affiliation-instance-id": "S2468125321001965-81f722e8e1286f12bd4a4f0dc383de78",
                            "ce:source-text": "Department of Internal Medicine I, Eberhard-Karls University, Tübingen, Germany",
                            "@dptid": "112670307"
                        },
                        "author": [{
                            "ce:given-name": "Michael",
                            "preferred-name": {
                                "ce:given-name": "Michael",
                                "ce:initials": "M.",
                                "ce:surname": "Bitzer",
                                "ce:indexed-name": "Bitzer M."
                            },
                            "@seq": "14",
                            "@author-instance-id": "S2468125321001965-171f027bc60cea5c64e587987d40392b",
                            "ce:initials": "M.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Bitzer",
                            "@auid": "57203106194",
                            "ce:indexed-name": "Bitzer M."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Germany",
                            "@afid": "60017246",
                            "@country": "deu",
                            "city": "Tübingen",
                            "organization": [
                                {"$": "Center for Personalized Medicine"},
                                {"$": "Eberhard-Karls University"}
                            ],
                            "affiliation-id": {
                                "@afid": "60017246",
                                "@dptid": "116270093"
                            },
                            "@affiliation-instance-id": "S2468125321001965-0ef6d2ac78beac2a2f9567cbb3831afb",
                            "ce:source-text": "Center for Personalized Medicine, Eberhard-Karls University, Tübingen, Germany",
                            "@dptid": "116270093"
                        },
                        "author": [{
                            "ce:given-name": "Michael",
                            "preferred-name": {
                                "ce:given-name": "Michael",
                                "ce:initials": "M.",
                                "ce:surname": "Bitzer",
                                "ce:indexed-name": "Bitzer M."
                            },
                            "@seq": "14",
                            "@author-instance-id": "S2468125321001965-171f027bc60cea5c64e587987d40392b",
                            "ce:initials": "M.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Bitzer",
                            "@auid": "57203106194",
                            "ce:indexed-name": "Bitzer M."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60028190",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Internal Medicine"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": {
                                "@afid": "60028190",
                                "@dptid": "107887048"
                            },
                            "@affiliation-instance-id": "S2468125321001965-3a6d53b2874a3224c7077030e6ecb15c",
                            "ce:source-text": "Internal Medicine, Chulalongkorn University, Bangkok, Thailand",
                            "@dptid": "107887048"
                        },
                        "author": [{
                            "ce:given-name": "Surbpong",
                            "preferred-name": {
                                "ce:given-name": "Surbpong",
                                "ce:initials": "S.",
                                "ce:surname": "Tanasanvimon",
                                "ce:indexed-name": "Tanasanvimon S."
                            },
                            "@seq": "15",
                            "@author-instance-id": "S2468125321001965-d8466bce45cb56c37bd4372e6918dd34",
                            "ce:initials": "S.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Tanasanvimon",
                            "@auid": "23089332900",
                            "ce:indexed-name": "Tanasanvimon S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "122213671",
                            "@country": "usa",
                            "city": "San Francisco",
                            "organization": [
                                {"$": "Biostatistics and Data Management"},
                                {"$": "QED Therapeutics"}
                            ],
                            "affiliation-id": {
                                "@afid": "122213671",
                                "@dptid": "124055040"
                            },
                            "state": "CA",
                            "@affiliation-instance-id": "S2468125321001965-443626a45980f1e84f44c5311bb77b0f",
                            "ce:source-text": "Biostatistics and Data Management, QED Therapeutics, San Francisco, CA, USA",
                            "@dptid": "124055040"
                        },
                        "author": [{
                            "ce:given-name": "Ai",
                            "preferred-name": {
                                "ce:given-name": "Ai",
                                "ce:initials": "A.",
                                "ce:surname": "Li",
                                "ce:indexed-name": "Li A."
                            },
                            "@seq": "16",
                            "@author-instance-id": "S2468125321001965-db493eee6745c0f5a02d9b0c37c43081",
                            "ce:initials": "A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "PhD",
                            "ce:surname": "Li",
                            "@auid": "57218602375",
                            "ce:indexed-name": "Li A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "100822091",
                            "@country": "usa",
                            "city": "San Francisco",
                            "organization": [
                                {"$": "Clinical Development"},
                                {"$": "QED Therapeutics"}
                            ],
                            "affiliation-id": {
                                "@afid": "100822091",
                                "@dptid": "127082440"
                            },
                            "state": "CA",
                            "@affiliation-instance-id": "S2468125321001965-3d9e4a7ee33355a35bf086d58b204817",
                            "ce:source-text": "Clinical Development, QED Therapeutics, San Francisco, CA, USA",
                            "@dptid": "127082440"
                        },
                        "author": [
                            {
                                "ce:given-name": "Amit",
                                "preferred-name": {
                                    "ce:given-name": "Amit",
                                    "ce:initials": "A.",
                                    "ce:surname": "Pande",
                                    "ce:indexed-name": "Pande A."
                                },
                                "@seq": "17",
                                "@author-instance-id": "S2468125321001965-4a3fa8973e821177aa358042d1379fcc",
                                "ce:initials": "A.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD",
                                "ce:surname": "Pande",
                                "@auid": "57219673052",
                                "ce:indexed-name": "Pande A."
                            },
                            {
                                "ce:given-name": "Stacie Peacock",
                                "preferred-name": {
                                    "ce:given-name": "Stacie Peacock",
                                    "ce:initials": "S.P.",
                                    "ce:surname": "Shepherd",
                                    "ce:indexed-name": "Shepherd S.P."
                                },
                                "@seq": "19",
                                "@author-instance-id": "S2468125321001965-090421b9b4dd77f2ae24cef4d3c60f7b",
                                "ce:initials": "S.P.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD",
                                "ce:surname": "Shepherd",
                                "@auid": "57303434600",
                                "ce:indexed-name": "Shepherd S.P."
                            },
                            {
                                "ce:given-name": "Susan",
                                "preferred-name": {
                                    "ce:given-name": "Susan",
                                    "ce:initials": "S.",
                                    "ce:surname": "Moran",
                                    "ce:indexed-name": "Moran S."
                                },
                                "@seq": "20",
                                "@author-instance-id": "S2468125321001965-34e4bce2dacb8fdb1cd7f4eb28f62e85",
                                "ce:initials": "S.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD",
                                "ce:surname": "Moran",
                                "@auid": "7102511953",
                                "ce:indexed-name": "Moran S."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "122213671",
                            "@country": "usa",
                            "city": "San Francisco",
                            "organization": [
                                {"$": "Translational Medicine"},
                                {"$": "QED Therapeutics"}
                            ],
                            "affiliation-id": {
                                "@afid": "122213671",
                                "@dptid": "124120863"
                            },
                            "state": "CA",
                            "@affiliation-instance-id": "S2468125321001965-e274ebb712b068b5c9ba0025c6f93824",
                            "ce:source-text": "Translational Medicine, QED Therapeutics, San Francisco, CA, USA",
                            "@dptid": "124120863"
                        },
                        "author": [{
                            "ce:given-name": "Harris S",
                            "preferred-name": {
                                "ce:given-name": "Harris S.",
                                "ce:initials": "H.S.",
                                "ce:surname": "Soifer",
                                "ce:indexed-name": "Soifer H.S."
                            },
                            "@seq": "18",
                            "@author-instance-id": "S2468125321001965-21c8886fbae06740638dee7932f85cdb",
                            "ce:initials": "H.S.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "PhD",
                            "ce:surname": "Soifer",
                            "@auid": "6508033211",
                            "ce:indexed-name": "Soifer H.S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "China",
                            "@afid": "60108904",
                            "@country": "chn",
                            "city": "Shanghai",
                            "organization": [
                                {"$": "Jiahui International Cancer Center"},
                                {"$": "Jiahui Health"}
                            ],
                            "affiliation-id": {"@afid": "60108904"},
                            "@affiliation-instance-id": "S2468125321001965-161666c9ae49759887520f8fe2bf88db",
                            "ce:source-text": "Jiahui International Cancer Center, Jiahui Health, Shanghai, China"
                        },
                        "author": [{
                            "ce:given-name": "Andrew X",
                            "preferred-name": {
                                "ce:given-name": "Andrew X.",
                                "ce:initials": "A.X.",
                                "ce:surname": "Zhu",
                                "ce:indexed-name": "Zhu A.X."
                            },
                            "@seq": "21",
                            "@author-instance-id": "S2468125321001965-d92fc9cf6e16037f6e22a047e774f8d2",
                            "ce:initials": "A.X.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Zhu",
                            "@auid": "57216593782",
                            "ce:indexed-name": "Zhu A.X."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60009343",
                            "@country": "usa",
                            "city": "New York",
                            "organization": {"$": "Memorial Sloan Kettering Cancer Center"},
                            "affiliation-id": {"@afid": "60009343"},
                            "state": "NY",
                            "@affiliation-instance-id": "S2468125321001965-f56a284cee97e05f474b77b7434c1f48",
                            "ce:source-text": "Memorial Sloan Kettering Cancer Center, New York, NY, USA"
                        },
                        "author": [{
                            "ce:given-name": "Ghassan K",
                            "preferred-name": {
                                "ce:given-name": "Ghassan K.",
                                "ce:initials": "G.K.",
                                "ce:surname": "Abou-Alfa",
                                "ce:indexed-name": "Abou-Alfa G.K."
                            },
                            "@seq": "23",
                            "@author-instance-id": "S2468125321001965-21e261cbc71a99194f287eb204494cda",
                            "ce:initials": "G.K.",
                            "@date-locked": "2022-01-22T14:49:39.778",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Abou-Alfa",
                            "@auid": "8660213800",
                            "ce:indexed-name": "Abou-Alfa G.K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60007997",
                            "@country": "usa",
                            "city": "New York",
                            "organization": {"$": "Weill Medical College at Cornell University"},
                            "affiliation-id": [
                                {"@afid": "60007997"},
                                {"@afid": "60007776"}
                            ],
                            "state": "NY",
                            "@affiliation-instance-id": "S2468125321001965-f8106fd252b10e0406a91c3c5600e3e3",
                            "ce:source-text": "Weill Medical College at Cornell University, New York, NY, USA"
                        },
                        "author": [{
                            "ce:given-name": "Ghassan K",
                            "preferred-name": {
                                "ce:given-name": "Ghassan K.",
                                "ce:initials": "G.K.",
                                "ce:surname": "Abou-Alfa",
                                "ce:indexed-name": "Abou-Alfa G.K."
                            },
                            "@seq": "23",
                            "@author-instance-id": "S2468125321001965-21e261cbc71a99194f287eb204494cda",
                            "ce:initials": "G.K.",
                            "@date-locked": "2022-01-22T14:49:39.778",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Abou-Alfa",
                            "@auid": "8660213800",
                            "ce:indexed-name": "Abou-Alfa G.K."
                        }]
                    }
                ],
                "citation-title": "Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study",
                "abstracts": "© 2021 Elsevier LtdBackground: Treatment options are sparse for patients with advanced cholangiocarcinoma after progression on first-line gemcitabine-based therapy. FGFR2 fusions or rearrangements occur in 10\u201316% of patients with intrahepatic cholangiocarcinoma. Infigratinib is a selective, ATP-competitive inhibitor of fibroblast growth factor receptors. We aimed to evaluate the antitumour activity of infigratinib in patients with locally advanced or metastatic cholangiocarcinoma, FGFR2 alterations, and previous gemcitabine-based treatment. Methods: This multicentre, open-label, single-arm, phase 2 study recruited patients from 18 academic centres and hospitals in the USA, Belgium, Spain, Germany, Singapore, Taiwan, and Thailand. Eligible participants were aged 18 years or older, had histologically or cytologically confirmed, locally advanced or metastatic cholangiocarcinoma and FGFR2 fusions or rearrangements, and were previously treated with at least one gemcitabine-containing regimen. Patients received 125 mg of oral infigratinib once daily for 21 days of 28-day cycles until disease progression, intolerance, withdrawal of consent, or death. Radiological tumour evaluation was done at baseline and every 8 weeks until disease progression via CT or MRI of the chest, abdomen, and pelvis. The primary endpoint was objective response rate, defined as the proportion of patients with a best overall response of a confirmed complete or partial response, as assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors, version 1.1. The primary outcome and safety were analysed in the full analysis set, which comprised all patients who received at least one dose of infigratinib. This trial is registered with ClinicalTrials.gov, NCT02150967, and is ongoing. Findings: Between June 23, 2014, and March 31, 2020, 122 patients were enrolled into our study, of whom 108 with FGFR2 fusions or rearrangements received at least one dose of infigratinib and comprised the full analysis set. After a median follow-up of 10·6 months (IQR 6·2\u201315·6), the BICR-assessed objective response rate was 23·1% (95% CI 15·6\u201332·2; 25 of 108 patients), with one confirmed complete response in a patient who only had non-target lesions identified at baseline and 24 partial responses. The most common treatment-emergent adverse events of any grade were hyperphosphataemia (n=83), stomatitis (n=59), fatigue (n=43), and alopecia (n=41). The most common ocular toxicity was dry eyes (n=37). Central serous retinopathy-like and retinal pigment epithelial detachment-like events occurred in 18 (17%) patients, of which ten (9%) were grade 1, seven (6%) were grade 2, and one (1%) was grade 3. There were no treatment-related deaths. Interpretation: Infigratinib has promising clinical activity and a manageable adverse event profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma harbouring FGFR2 gene fusions or rearrangements, and so represents a potential new therapeutic option in this setting. Funding: QED Therapeutics and Novartis.",
                "correspondence": {
                    "affiliation": {
                        "country": "United States",
                        "postal-code": "77030",
                        "@country": "usa",
                        "city": "Houston",
                        "organization": [
                            {"$": "Department of Gastrointestinal Medical Oncology"},
                            {"$": "MD Anderson Cancer Center"}
                        ],
                        "state": "TX"
                    },
                    "person": {
                        "ce:given-name": "Milind",
                        "ce:initials": "M.",
                        "ce:degrees": "MD",
                        "ce:surname": "Javle",
                        "ce:indexed-name": "Javle M."
                    }
                },
                "citation-info": {
                    "citation-type": {"@code": "ar"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "sourcetitle-abbrev": "Lancet Gastroenterol. Hepatol.",
                    "website": {"ce:e-address": {
                        "$": "http://www.journals.elsevier.com/the-lancet-gastroenterology-and-hepatology",
                        "@type": "email"
                    }},
                    "@country": "gbr",
                    "translated-sourcetitle": {"@xml:lang": "eng"},
                    "issn": {
                        "$": "24681253",
                        "@type": "print"
                    },
                    "volisspag": {
                        "voliss": {
                            "@volume": "6",
                            "@issue": "10"
                        },
                        "pagerange": {
                            "@first": "803",
                            "@last": "815"
                        }
                    },
                    "@type": "j",
                    "publicationyear": {"@first": "2021"},
                    "publisher": {"publishername": "Elsevier Ltd"},
                    "sourcetitle": "The Lancet Gastroenterology and Hepatology",
                    "@srcid": "21100786228",
                    "publicationdate": {
                        "month": "10",
                        "year": "2021",
                        "date-text": "October 2021",
                        "day": "01"
                    }
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "16",
                                    "classification-description": "Cancer"
                                },
                                {
                                    "classification-code": "2",
                                    "classification-description": "Physiology"
                                },
                                {
                                    "classification-code": "29",
                                    "classification-description": "Clinical and Experimental Biochemistry"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                },
                                {
                                    "classification-code": "38",
                                    "classification-description": "Adverse Reactions Titles"
                                },
                                {
                                    "classification-code": "6",
                                    "classification-description": "Internal Medicine"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": [
                                {"$": "2721"},
                                {"$": "2715"}
                            ]
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "tradenamegroup": {"tradenames": {
                        "trademanuitem": {"tradename": "Foundation One"},
                        "@type": "TNV"
                    }},
                    "chemicalgroup": {"chemicals": [
                        {
                            "@source": "esbd",
                            "chemical": [
                                {
                                    "cas-registry-number": "41575-94-4",
                                    "chemical-name": "carboplatin"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "15663-27-1"},
                                        {"$": "26035-31-4"},
                                        {"$": "96081-74-2"}
                                    ],
                                    "chemical-name": "cisplatin"
                                },
                                {
                                    "cas-registry-number": "79079-06-4",
                                    "chemical-name": "epidermal growth factor receptor"
                                },
                                {
                                    "cas-registry-number": "306781-00-0",
                                    "chemical-name": "fibroblast growth factor receptor 3"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "872511-34-7"},
                                        {"$": "1310746-10-1"}
                                    ],
                                    "chemical-name": "infigratinib"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "182683-00-7"},
                                        {"$": "152751-57-0"},
                                        {"$": "198342-66-4"},
                                        {"$": "198343-01-0"},
                                        {"$": "224313-14-8"},
                                        {"$": "52757-95-6"}
                                    ],
                                    "chemical-name": "sevelamer"
                                },
                                {
                                    "cas-registry-number": "951-77-9",
                                    "chemical-name": "deoxycytidine"
                                },
                                {
                                    "cas-registry-number": "103882-84-4",
                                    "chemical-name": "gemcitabine"
                                }
                            ]
                        },
                        {
                            "@source": "nlm",
                            "chemical": [
                                {"chemical-name": "Deoxycytidine"},
                                {"chemical-name": "FGFR2 protein, human"},
                                {"chemical-name": "gemcitabine"},
                                {"chemical-name": "infigratinib"},
                                {"chemical-name": "Phenylurea Compounds"},
                                {"chemical-name": "Pyrimidines"},
                                {"chemical-name": "Radiation-Sensitizing Agents"},
                                {"chemical-name": "Receptor, Fibroblast Growth Factor, Type 1"},
                                {"chemical-name": "Receptor, Fibroblast Growth Factor, Type 2"}
                            ]
                        }
                    ]}
                },
                "grantlist": {
                    "@complete": "y",
                    "grant-text": {
                        "$": "This study was funded by Novartis and QED Therapeutics, an affiliate of BridgeBio, and was presented, in part, at the 2020 Cholangiocarcinoma Foundation Annual Conference (July 22\u201324, 2020) and at the 2021 Gastrointestinal Cancers Symposium (Jan 15\u201317, 2021). We thank all patients who participated in this study, the patients' families, the clinical investigators, the clinical research nurses, the clinical research monitors, the data management team, and all other members of the 2204 clinical study team. We also thank Roo Vold at QED Therapeutics for helping with data verification and editorial review, and Lee Miller and Deirdre Carman at Miller Medical Communications for their medical editing and writing assistance, which was funded by QED Therapeutics.",
                        "@xml:lang": "eng"
                    }
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2022 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "MEDLINE",
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "NURSNG"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "SNEMB"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "01",
                    "@year": "2022",
                    "@timestamp": "BST 11:38:19",
                    "@month": "02"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2014482967",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "635813471",
                            "@idtype": "associatedPUI"
                        },
                        {
                            "$": "937342717",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20211155412",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "34358484",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "2021542955",
                            "@idtype": "NURSNG"
                        },
                        {
                            "$": "20214955631",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20214211369",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "2021186227",
                            "@idtype": "SNEMB"
                        },
                        {
                            "$": "85116718584",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85116718584",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "635813471",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "657866409",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:pii": "S2468125321001965",
                    "ce:ern": "pii:S2468125321001965",
                    "ce:doi": "10.1016/S2468-1253(21)00196-5"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "35",
                "reference": [
                    {
                        "ref-fulltext": "Patel, N, Benipal, B, Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 states. Cureus, 11, 2019, e3962.",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 states"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib1",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "e3962",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85073660958",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "11"}},
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "N.",
                                    "@_fa": "true",
                                    "ce:surname": "Patel",
                                    "ce:indexed-name": "Patel N."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "B.",
                                    "@_fa": "true",
                                    "ce:surname": "Benipal",
                                    "ce:indexed-name": "Benipal B."
                                }
                            ]},
                            "ref-sourcetitle": "Cureus"
                        },
                        "ce:source-text": "Patel N, Benipal B. Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 states. Cureus 2019; 11: e3962."
                    },
                    {
                        "ref-fulltext": "Banales, JM, Marin, JJG, Lamarca, A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17 (2020), 557\u2013588.",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Cholangiocarcinoma 2020: the next horizon in mechanisms and management"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib2",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85087305764",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "17"},
                                "pagerange": {
                                    "@first": "557",
                                    "@last": "588"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Banales",
                                        "ce:indexed-name": "Banales J.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.J.G.",
                                        "@_fa": "true",
                                        "ce:surname": "Marin",
                                        "ce:indexed-name": "Marin J.J.G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Lamarca",
                                        "ce:indexed-name": "Lamarca A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Rev Gastroenterol Hepatol"
                        },
                        "ce:source-text": "Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020; 17: 557\u201388."
                    },
                    {
                        "ref-fulltext": "Gad, MM, Saad, AM, Faisaluddin, M, et al. Epidemiology of cholangiocarcinoma; United States incidence and mortality trends. Clin Res Hepatol Gastroenterol 44 (2020), 885\u2013893.",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Epidemiology of cholangiocarcinoma; United States incidence and mortality trends"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib3",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85083829251",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "44"},
                                "pagerange": {
                                    "@first": "885",
                                    "@last": "893"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Gad",
                                        "ce:indexed-name": "Gad M.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Saad",
                                        "ce:indexed-name": "Saad A.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Faisaluddin",
                                        "ce:indexed-name": "Faisaluddin M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Res Hepatol Gastroenterol"
                        },
                        "ce:source-text": "Gad MM, Saad AM, Faisaluddin M, et al. Epidemiology of cholangiocarcinoma; United States incidence and mortality trends. Clin Res Hepatol Gastroenterol 2020; 44: 885\u201393."
                    },
                    {
                        "ref-fulltext": "American Cancer Society. Key statistics for bile duct cancer. https://www.cancer.org/cancer/bile-duct-cancer/about/key-statistics.html, 2020. (Accessed 20 October 2020)",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.cancer.org/cancer/bile-duct-cancer/about/key-statistics.html",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Key statistics for bile duct cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib4",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85121235825",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "(Accessed 20 October 2020)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "American Cancer Society",
                                "ce:indexed-name": "American Cancer Society"
                            }}
                        },
                        "ce:source-text": "American Cancer Society. Key statistics for bile duct cancer. 2020. https://www.cancer.org/cancer/bile-duct-cancer/about/key-statistics.html (accessed Oct 20, 2020)."
                    },
                    {
                        "ref-fulltext": "Valle, J, Wasan, H, Palmer, DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362 (2010), 1273\u20131281.",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-title": {"ref-titletext": "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib5",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "77950822827",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "362"},
                                "pagerange": {
                                    "@first": "1273",
                                    "@last": "1281"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Valle",
                                        "ce:indexed-name": "Valle J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Wasan",
                                        "ce:indexed-name": "Wasan H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Palmer",
                                        "ce:indexed-name": "Palmer D.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273\u201381."
                    },
                    {
                        "ref-fulltext": "National Comprehensive Cancer Network. NCCN guidelines version 5.2021. Hepatobiliary cancers. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf, 2021. (Accessed 13 July 2021)",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "NCCN guidelines version 5.2021. Hepatobiliary cancers"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib6",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85121254670",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "(Accessed 13 July 2021)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "National Comprehensive Cancer Network",
                                "ce:indexed-name": "National Comprehensive Cancer Network"
                            }}
                        },
                        "ce:source-text": "National Comprehensive Cancer Network. NCCN guidelines version 5.2021. Hepatobiliary cancers. 2021. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf (accessed July 13, 2021)."
                    },
                    {
                        "ref-fulltext": "Lamarca, A, Palmer, DH, Wasan, HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 22 (2021), 690\u2013701.",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib7",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85105835306",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "22"},
                                "pagerange": {
                                    "@first": "690",
                                    "@last": "701"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Lamarca",
                                        "ce:indexed-name": "Lamarca A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Palmer",
                                        "ce:indexed-name": "Palmer D.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Wasan",
                                        "ce:indexed-name": "Wasan H.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021; 22: 690\u2013701."
                    },
                    {
                        "ref-fulltext": "Lowery, MA, Goff, LW, Keenan, BP, et al. Second-line chemotherapy in advanced biliary cancers: a retrospective, multicenter analysis of outcomes. Cancer 125 (2019), 4426\u20134434.",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Second-line chemotherapy in advanced biliary cancers: a retrospective, multicenter analysis of outcomes"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib8",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85071271490",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "125"},
                                "pagerange": {
                                    "@first": "4426",
                                    "@last": "4434"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Lowery",
                                        "ce:indexed-name": "Lowery M.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Goff",
                                        "ce:indexed-name": "Goff L.W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Keenan",
                                        "ce:indexed-name": "Keenan B.P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer"
                        },
                        "ce:source-text": "Lowery MA, Goff LW, Keenan BP, et al. Second-line chemotherapy in advanced biliary cancers: a retrospective, multicenter analysis of outcomes. Cancer 2019; 125: 4426\u201334."
                    },
                    {
                        "ref-fulltext": "Javle, M, Bekaii-Saab, T, Jain, A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer 122 (2016), 3838\u20133847.",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Biliary cancer: utility of next-generation sequencing for clinical management"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib9",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84992509268",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "122"},
                                "pagerange": {
                                    "@first": "3838",
                                    "@last": "3847"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Javle",
                                        "ce:indexed-name": "Javle M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Bekaii-Saab",
                                        "ce:indexed-name": "Bekaii-Saab T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Jain",
                                        "ce:indexed-name": "Jain A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer"
                        },
                        "ce:source-text": "Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer 2016; 122: 3838\u201347."
                    },
                    {
                        "ref-fulltext": "Nakamura, H, Arai, Y, Totoki, Y, et al. Genomic spectra of biliary tract cancer. Nat Genet 47 (2015), 1003\u20131010.",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Genomic spectra of biliary tract cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib10",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84940556535",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "47"},
                                "pagerange": {
                                    "@first": "1003",
                                    "@last": "1010"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Nakamura",
                                        "ce:indexed-name": "Nakamura H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Arai",
                                        "ce:indexed-name": "Arai Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Totoki",
                                        "ce:indexed-name": "Totoki Y."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Genet"
                        },
                        "ce:source-text": "Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet 2015; 47: 1003\u201310."
                    },
                    {
                        "ref-fulltext": "Borad, MJ, Champion, MD, Egan, JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet, 10, 2014, e1004135.",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib11",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "e1004135",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "84901742112",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "10"}},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Borad",
                                        "ce:indexed-name": "Borad M.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Champion",
                                        "ce:indexed-name": "Champion M.D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Egan",
                                        "ce:indexed-name": "Egan J.B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "PLoS Genet"
                        },
                        "ce:source-text": "Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet 2014; 10: e1004135."
                    },
                    {
                        "ref-fulltext": "Ross, JS, Wang, K, Khaira, D, et al. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer 122 (2016), 702\u2013711.",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib12",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84958863406",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "122"},
                                "pagerange": {
                                    "@first": "702",
                                    "@last": "711"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Ross",
                                        "ce:indexed-name": "Ross J.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Khaira",
                                        "ce:indexed-name": "Khaira D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer"
                        },
                        "ce:source-text": "Ross JS, Wang K, Khaira D, et al. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer 2016; 122: 702\u201311."
                    },
                    {
                        "ref-fulltext": "Farshidfar, F, Zheng, S, Gingras, MC, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep 18 (2017), 2780\u20132794.",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib13",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85015247880",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "18"},
                                "pagerange": {
                                    "@first": "2780",
                                    "@last": "2794"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Farshidfar",
                                        "ce:indexed-name": "Farshidfar F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Zheng",
                                        "ce:indexed-name": "Zheng S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Gingras",
                                        "ce:indexed-name": "Gingras M.C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cell Rep"
                        },
                        "ce:source-text": "Farshidfar F, Zheng S, Gingras MC, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep 2017; 18: 2780\u201394."
                    },
                    {
                        "ref-fulltext": "Kongpetch, S, Jusakul, A, Lim, JQ, et al. Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma. JCO Glob Oncol 6 (2020), 628\u2013638.",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib14",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85083501481",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "6"},
                                "pagerange": {
                                    "@first": "628",
                                    "@last": "638"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Kongpetch",
                                        "ce:indexed-name": "Kongpetch S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Jusakul",
                                        "ce:indexed-name": "Jusakul A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.Q.",
                                        "@_fa": "true",
                                        "ce:surname": "Lim",
                                        "ce:indexed-name": "Lim J.Q."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JCO Glob Oncol"
                        },
                        "ce:source-text": "Kongpetch S, Jusakul A, Lim JQ, et al. Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma. JCO Glob Oncol 2020; 6: 628\u201338."
                    },
                    {
                        "ref-fulltext": "Javle, M, Sadeghi, S, Roychowdhury, S, et al. SO-5 Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: a retrospective analysis. Ann Oncol, 31, 2020, S219.",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "SO-5 Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: a retrospective analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib15",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85121282181",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "31"},
                                "pagerange": {"@first": "S219"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Javle",
                                        "ce:indexed-name": "Javle M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Sadeghi",
                                        "ce:indexed-name": "Sadeghi S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Roychowdhury",
                                        "ce:indexed-name": "Roychowdhury S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Javle M, Sadeghi S, Roychowdhury S, et al. SO-5 Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: a retrospective analysis. Ann Oncol 2020; 31: S219."
                    },
                    {
                        "ref-fulltext": "Abou-Alfa, GK, Bibeau, K, Schultz, N, et al. Effect of FGFR2 alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma. Proc Am Soc Clin Oncol, 39(suppl 3), 2021, 303.",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Effect of FGFR2 alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib16",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85119878785",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "39"},
                                "pagerange": {"@first": "303"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Abou-Alfa",
                                        "ce:indexed-name": "Abou-Alfa G.K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Bibeau",
                                        "ce:indexed-name": "Bibeau K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Schultz",
                                        "ce:indexed-name": "Schultz N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Proc Am Soc Clin Oncol"
                        },
                        "ce:source-text": "Abou-Alfa GK, Bibeau K, Schultz N, et al. Effect of FGFR2 alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma. Proc Am Soc Clin Oncol 2021; 39 (suppl 3): 303."
                    },
                    {
                        "ref-fulltext": "Goyal, L, Saha, SK, Liu, LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov 7 (2017), 252\u2013263.",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib17",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85014739217",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "7"},
                                "pagerange": {
                                    "@first": "252",
                                    "@last": "263"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Goyal",
                                        "ce:indexed-name": "Goyal L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Saha",
                                        "ce:indexed-name": "Saha S.K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu L.Y."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Discov"
                        },
                        "ce:source-text": "Goyal L, Saha SK, Liu LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov 2017; 7: 252\u201363."
                    },
                    {
                        "ref-fulltext": "Lamarca, A, Kapacee, Z, Breeze, M, et al. Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers. J Clin Med, 9, 2020, 2854.",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib18",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "2854",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85098494220",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "9"}},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Lamarca",
                                        "ce:indexed-name": "Lamarca A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Kapacee",
                                        "ce:indexed-name": "Kapacee Z."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Breeze",
                                        "ce:indexed-name": "Breeze M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Med"
                        },
                        "ce:source-text": "Lamarca A, Kapacee Z, Breeze M, et al. Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers. J Clin Med 2020; 9: 2854."
                    },
                    {
                        "ref-fulltext": "Loriot, Y, Necchi, A, Park, SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 381 (2019), 338\u2013348.",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Erdafitinib in locally advanced or metastatic urothelial carcinoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib19",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85069906840",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "381"},
                                "pagerange": {
                                    "@first": "338",
                                    "@last": "348"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Loriot",
                                        "ce:indexed-name": "Loriot Y."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Necchi",
                                        "ce:indexed-name": "Necchi A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Park",
                                        "ce:indexed-name": "Park S.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019; 381: 338\u201348."
                    },
                    {
                        "ref-fulltext": "Abou-Alfa, GK, Sahai, V, Hollebecque, A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21 (2020), 671\u2013684.",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib20",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85082806833",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "21"},
                                "pagerange": {
                                    "@first": "671",
                                    "@last": "684"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Abou-Alfa",
                                        "ce:indexed-name": "Abou-Alfa G.K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Sahai",
                                        "ce:indexed-name": "Sahai V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hollebecque",
                                        "ce:indexed-name": "Hollebecque A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020; 21: 671\u201384."
                    },
                    {
                        "ref-fulltext": "Taiho Oncology. FDA grants breakthrough therapy designation for Taiho Oncology's futibatinib for treatment of advanced cholangiocarcinoma. https://www.taihooncology.com/us/news/2021-04-01_toi_tpc_futibatinib_btd/, April 1, 2021. (Accessed 13 July 2021)",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.taihooncology.com/us/news/2021-04-01_toi_tpc_futibatinib_btd/",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "FDA grants breakthrough therapy designation for Taiho Oncology's futibatinib for treatment of advanced cholangiocarcinoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib21",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85121276259",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "(Accessed 13 July 2021)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Taiho Oncology",
                                "ce:indexed-name": "Taiho Oncology"
                            }}
                        },
                        "ce:source-text": "Taiho Oncology. FDA grants breakthrough therapy designation for Taiho Oncology's futibatinib for treatment of advanced cholangiocarcinoma. April 1, 2021. https://www.taihooncology.com/us/news/2021-04-01_toi_tpc_futibatinib_btd/ (accessed July 13, 2021)."
                    },
                    {
                        "ref-fulltext": "Guagnano, V, Furet, P, Spanka, C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 54 (2011), 7066\u20137083.",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib22",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "80054900437",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "54"},
                                "pagerange": {
                                    "@first": "7066",
                                    "@last": "7083"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Guagnano",
                                        "ce:indexed-name": "Guagnano V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Furet",
                                        "ce:indexed-name": "Furet P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Spanka",
                                        "ce:indexed-name": "Spanka C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Med Chem"
                        },
                        "ce:source-text": "Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011; 54: 7066\u201383."
                    },
                    {
                        "ref-fulltext": "Guagnano, V, Kauffmann, A, Wöhrle, S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2 (2012), 1118\u20131133.",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-title": {"ref-titletext": "FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib23",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84871491773",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "2"},
                                "pagerange": {
                                    "@first": "1118",
                                    "@last": "1133"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Guagnano",
                                        "ce:indexed-name": "Guagnano V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Kauffmann",
                                        "ce:indexed-name": "Kauffmann A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Wöhrle",
                                        "ce:indexed-name": "Wohrle S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Discov"
                        },
                        "ce:source-text": "Guagnano V, Kauffmann A, Wöhrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2012; 2: 1118\u201333."
                    },
                    {
                        "ref-fulltext": "Nogova, L, Sequist, LV, Perez Garcia, JM, et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1\u20133 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. J Clin Oncol 35 (2017), 157\u2013165.",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Evaluation of BGJ398, a fibroblast growth factor receptor 1\u20133 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib24",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85009882036",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "35"},
                                "pagerange": {
                                    "@first": "157",
                                    "@last": "165"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Nogova",
                                        "ce:indexed-name": "Nogova L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Sequist",
                                        "ce:indexed-name": "Sequist L.V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Perez Garcia",
                                        "ce:indexed-name": "Perez Garcia J.M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Nogova L, Sequist LV, Perez Garcia JM, et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1\u20133 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. J Clin Oncol 2017; 35: 157\u201365."
                    },
                    {
                        "ref-fulltext": "Javle, M, Lowery, M, Shroff, RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 36 (2018), 276\u2013282.",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib25",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85040814328",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "36"},
                                "pagerange": {
                                    "@first": "276",
                                    "@last": "282"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Javle",
                                        "ce:indexed-name": "Javle M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Lowery",
                                        "ce:indexed-name": "Lowery M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Shroff",
                                        "ce:indexed-name": "Shroff R.T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 2018; 36: 276\u201382."
                    },
                    {
                        "ref-fulltext": "Javle, M, Kelley, RK, Roychowdhury, S, et al. Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Ann Oncol, 29(suppl 8), 2018, viii720 (abstr).",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib26",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "viii720",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85077155122",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "29"}},
                            "ref-text": "(abstr).",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Javle",
                                        "ce:indexed-name": "Javle M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Kelley",
                                        "ce:indexed-name": "Kelley R.K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Roychowdhury",
                                        "ce:indexed-name": "Roychowdhury S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Javle M, Kelley RK, Roychowdhury S, et al. Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Ann Oncol 2018; 29 (suppl 8): viii720 (abstr)."
                    },
                    {
                        "ref-fulltext": "Meng, Z-W, Pan, W, Hong, H-J, Chen, J-Z, Chen, Y-L, Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems. Medicine (Baltimore), 96, 2017, e7891.",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib27",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "e7891",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85028708265",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "96"}},
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "Z.-W.",
                                    "@_fa": "true",
                                    "ce:surname": "Meng",
                                    "ce:indexed-name": "Meng Z.-W."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "W.",
                                    "@_fa": "true",
                                    "ce:surname": "Pan",
                                    "ce:indexed-name": "Pan W."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "H.-J.",
                                    "@_fa": "true",
                                    "ce:surname": "Hong",
                                    "ce:indexed-name": "Hong H.-J."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "J.-Z.",
                                    "@_fa": "true",
                                    "ce:surname": "Chen",
                                    "ce:indexed-name": "Chen J.-Z."
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "Y.-L.",
                                    "@_fa": "true",
                                    "ce:surname": "Chen",
                                    "ce:indexed-name": "Chen Y.-L."
                                }
                            ]},
                            "ref-sourcetitle": "Medicine (Baltimore)"
                        },
                        "ce:source-text": "Meng Z-W, Pan W, Hong H-J, Chen J-Z, Chen Y-L. Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems. Medicine (Baltimore) 2017; 96: e7891."
                    },
                    {
                        "ref-fulltext": "Amit, O, Mannino, F, Stone, AM, et al. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. Eur J Cancer 47 (2011), 1772\u20131778.",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib28",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "80051550048",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "47"},
                                "pagerange": {
                                    "@first": "1772",
                                    "@last": "1778"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "O.",
                                        "@_fa": "true",
                                        "ce:surname": "Amit",
                                        "ce:indexed-name": "Amit O."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Mannino",
                                        "ce:indexed-name": "Mannino F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Stone",
                                        "ce:indexed-name": "Stone A.M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur J Cancer"
                        },
                        "ce:source-text": "Amit O, Mannino F, Stone AM, et al. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. Eur J Cancer 2011; 47: 1772\u201378."
                    },
                    {
                        "ref-fulltext": "Furuse, I, Goyal, L, Meric-Bernstam, F, et al. 116MO Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harbouring FGFR2 fusions/rearrangements: FOENIX-CCA2. Ann Oncol 31:suppl 6 (2020), 1288\u20131289.",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "116MO Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harbouring FGFR2 fusions/rearrangements: FOENIX-CCA2"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib29",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85103521202",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "31"},
                                "pagerange": {
                                    "@first": "1288",
                                    "@last": "1289"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Furuse",
                                        "ce:indexed-name": "Furuse I."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Goyal",
                                        "ce:indexed-name": "Goyal L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Meric-Bernstam",
                                        "ce:indexed-name": "Meric-Bernstam F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Furuse I, Goyal L, Meric-Bernstam F, et al. 116MO Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harbouring FGFR2 fusions/rearrangements: FOENIX-CCA2. Ann Oncol 2020; 31 (suppl 6): 1288\u201389."
                    },
                    {
                        "ref-fulltext": "Pal, SK, Rosenberg, JE, Hoffman-Censits, JH, et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1\u20133 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov 8 (2018), 812\u2013821.",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Efficacy of BGJ398, a fibroblast growth factor receptor 1\u20133 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib30",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85049495380",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "8"},
                                "pagerange": {
                                    "@first": "812",
                                    "@last": "821"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Pal",
                                        "ce:indexed-name": "Pal S.K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Rosenberg",
                                        "ce:indexed-name": "Rosenberg J.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Hoffman-Censits",
                                        "ce:indexed-name": "Hoffman-Censits J.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Discov"
                        },
                        "ce:source-text": "Pal SK, Rosenberg JE, Hoffman-Censits JH, et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1\u20133 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov 2018; 8: 812\u201321."
                    },
                    {
                        "ref-fulltext": "Lacouture, ME, Sibaud, V, Anadkat, MJ, et al. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines. Oncologist 26 (2021), e316\u2013e326.",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib31",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85094660492",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "26"},
                                "pagerange": {
                                    "@first": "e316",
                                    "@last": "e326"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Lacouture",
                                        "ce:indexed-name": "Lacouture M.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Sibaud",
                                        "ce:indexed-name": "Sibaud V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Anadkat",
                                        "ce:indexed-name": "Anadkat M.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Oncologist"
                        },
                        "ce:source-text": "Lacouture ME, Sibaud V, Anadkat MJ, et al. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines. Oncologist 2021; 26: e316\u201326."
                    },
                    {
                        "ref-fulltext": "Magone, MT, Hartley, IR, Fitzgibbon, E, et al. Ocular adverse effects of infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor. Ophthalmology 128 (2021), 624\u2013626.",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Ocular adverse effects of infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib32",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85092444179",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "128"},
                                "pagerange": {
                                    "@first": "624",
                                    "@last": "626"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Magone",
                                        "ce:indexed-name": "Magone M.T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "I.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Hartley",
                                        "ce:indexed-name": "Hartley I.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Fitzgibbon",
                                        "ce:indexed-name": "Fitzgibbon E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ophthalmology"
                        },
                        "ce:source-text": "Magone MT, Hartley IR, Fitzgibbon E, et al. Ocular adverse effects of infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor. Ophthalmology 2021; 128: 624\u201326."
                    },
                    {
                        "ref-fulltext": "Lyou, Y, Grivas, P, Rosenberg, JE, et al. Hyperphosphatemia secondary to the selective fibroblast growth factor receptor 1\u20133 inhibitor infigratinib (BGJ398) is associated with antitumor efficacy in fibroblast growth factor receptor 3-altered advanced/metastatic urothelial carcinoma. Eur Urol 78 (2020), 916\u2013924.",
                        "@id": "33",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Hyperphosphatemia secondary to the selective fibroblast growth factor receptor 1\u20133 inhibitor infigratinib (BGJ398) is associated with antitumor efficacy in fibroblast growth factor receptor 3-altered advanced/metastatic urothelial carcinoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib33",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85089730911",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "78"},
                                "pagerange": {
                                    "@first": "916",
                                    "@last": "924"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Lyou",
                                        "ce:indexed-name": "Lyou Y."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Grivas",
                                        "ce:indexed-name": "Grivas P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Rosenberg",
                                        "ce:indexed-name": "Rosenberg J.E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur Urol"
                        },
                        "ce:source-text": "Lyou Y, Grivas P, Rosenberg JE, et al. Hyperphosphatemia secondary to the selective fibroblast growth factor receptor 1\u20133 inhibitor infigratinib (BGJ398) is associated with antitumor efficacy in fibroblast growth factor receptor 3-altered advanced/metastatic urothelial carcinoma. Eur Urol 2020; 78: 916\u201324."
                    },
                    {
                        "ref-fulltext": "Lamarca, A, Barriuso, J, McNamara, MG, Valle, JW, Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer. J Hepatol 73 (2020), 170\u2013185.",
                        "@id": "34",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib34",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85086748692",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "73"},
                                "pagerange": {
                                    "@first": "170",
                                    "@last": "185"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Lamarca",
                                    "ce:indexed-name": "Lamarca A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Barriuso",
                                    "ce:indexed-name": "Barriuso J."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M.G.",
                                    "@_fa": "true",
                                    "ce:surname": "McNamara",
                                    "ce:indexed-name": "McNamara M.G."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "J.W.",
                                    "@_fa": "true",
                                    "ce:surname": "Valle",
                                    "ce:indexed-name": "Valle J.W."
                                }
                            ]},
                            "ref-sourcetitle": "J Hepatol"
                        },
                        "ce:source-text": "Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer. J Hepatol 2020; 73: 170\u201385."
                    },
                    {
                        "ref-fulltext": "Kim, RD, Sarker, D, Meyer, T, et al. First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov 9 (2019), 1696\u20131707.",
                        "@id": "35",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib35",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85075943998",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "9"},
                                "pagerange": {
                                    "@first": "1696",
                                    "@last": "1707"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim R.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Sarker",
                                        "ce:indexed-name": "Sarker D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Meyer",
                                        "ce:indexed-name": "Meyer T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Discov"
                        },
                        "ce:source-text": "Kim RD, Sarker D, Meyer T, et al. First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov 2019; 9: 1696\u2013707."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "Scottsdale",
            "@id": "60026952",
            "affilname": "Mayo Clinic Scottsdale-Phoenix, Arizona",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026952",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Tubingen",
            "@id": "60017246",
            "affilname": "Eberhard Karls Universität Tübingen",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017246",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60008130",
            "affilname": "Massachusetts General Hospital Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008130",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Columbus",
            "@id": "60002058",
            "affilname": "The Ohio State University Comprehensive Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002058",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "San Francisco",
            "@id": "122213671",
            "affilname": "QED Therapeutics",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122213671",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Shanghai",
            "@id": "60108904",
            "affilname": "Fudan University Shanghai Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60108904",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60106366",
            "affilname": "National University Health System",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60106366",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60106362",
            "affilname": "Cancer Science Institute of Singapore",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60106362",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Heidelberg",
            "@id": "60082880",
            "affilname": "Krankenhaus Salem",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60082880",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Detroit",
            "@id": "60033199",
            "affilname": "Barbara Ann Karmanos Cancer Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60033199",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "San Francisco",
            "@id": "60029881",
            "affilname": "UCSF Helen Diller Family Comprehensive Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029881",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Los Angeles",
            "@id": "60022143",
            "affilname": "USC Norris Comprehensive Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022143",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Houston",
            "@id": "60015023",
            "affilname": "The University of Texas MD Anderson Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015023",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Brussels",
            "@id": "60012936",
            "affilname": "Cliniques Universitaires Saint-Luc",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012936",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Barcelona",
            "@id": "60012486",
            "affilname": "Hospital Universitari Vall d'Hebron",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012486",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Koln",
            "@id": "60008658",
            "affilname": "Uniklinik Köln",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008658",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "New York",
            "@id": "60007997",
            "affilname": "Weill Cornell Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Los Angeles",
            "@id": "60005247",
            "affilname": "David Geffen School of Medicine at UCLA",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005247",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Heidelberg",
            "@id": "60003280",
            "affilname": "Universitätsklinikum Heidelberg",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60003280",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "San Francisco",
            "@id": "100822091",
            "affilname": "Clinical Development",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100822091",
            "affiliation-country": "United States"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85116718584",
        "dc:description": "Background: Treatment options are sparse for patients with advanced cholangiocarcinoma after progression on first-line gemcitabine-based therapy. FGFR2 fusions or rearrangements occur in 10\u201316% of patients with intrahepatic cholangiocarcinoma. Infigratinib is a selective, ATP-competitive inhibitor of fibroblast growth factor receptors. We aimed to evaluate the antitumour activity of infigratinib in patients with locally advanced or metastatic cholangiocarcinoma, FGFR2 alterations, and previous gemcitabine-based treatment. Methods: This multicentre, open-label, single-arm, phase 2 study recruited patients from 18 academic centres and hospitals in the USA, Belgium, Spain, Germany, Singapore, Taiwan, and Thailand. Eligible participants were aged 18 years or older, had histologically or cytologically confirmed, locally advanced or metastatic cholangiocarcinoma and FGFR2 fusions or rearrangements, and were previously treated with at least one gemcitabine-containing regimen. Patients received 125 mg of oral infigratinib once daily for 21 days of 28-day cycles until disease progression, intolerance, withdrawal of consent, or death. Radiological tumour evaluation was done at baseline and every 8 weeks until disease progression via CT or MRI of the chest, abdomen, and pelvis. The primary endpoint was objective response rate, defined as the proportion of patients with a best overall response of a confirmed complete or partial response, as assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors, version 1.1. The primary outcome and safety were analysed in the full analysis set, which comprised all patients who received at least one dose of infigratinib. This trial is registered with ClinicalTrials.gov, NCT02150967, and is ongoing. Findings: Between June 23, 2014, and March 31, 2020, 122 patients were enrolled into our study, of whom 108 with FGFR2 fusions or rearrangements received at least one dose of infigratinib and comprised the full analysis set. After a median follow-up of 10·6 months (IQR 6·2\u201315·6), the BICR-assessed objective response rate was 23·1% (95% CI 15·6\u201332·2; 25 of 108 patients), with one confirmed complete response in a patient who only had non-target lesions identified at baseline and 24 partial responses. The most common treatment-emergent adverse events of any grade were hyperphosphataemia (n=83), stomatitis (n=59), fatigue (n=43), and alopecia (n=41). The most common ocular toxicity was dry eyes (n=37). Central serous retinopathy-like and retinal pigment epithelial detachment-like events occurred in 18 (17%) patients, of which ten (9%) were grade 1, seven (6%) were grade 2, and one (1%) was grade 3. There were no treatment-related deaths. Interpretation: Infigratinib has promising clinical activity and a manageable adverse event profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma harbouring FGFR2 gene fusions or rearrangements, and so represents a potential new therapeutic option in this setting. Funding: QED Therapeutics and Novartis.",
        "pubmed-id": "34358484",
        "prism:coverDate": "2021-10-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85116718584",
        "dc:creator": {"author": [{
            "ce:given-name": "Milind",
            "preferred-name": {
                "ce:given-name": "Milind",
                "ce:initials": "M.",
                "ce:surname": "Javle",
                "ce:indexed-name": "Javle M."
            },
            "@seq": "1",
            "ce:initials": "M.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60015023",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015023"
            },
            "ce:degrees": "MD",
            "ce:surname": "Javle",
            "@auid": "35425978300",
            "author-url": "https://api.elsevier.com/content/author/author_id/35425978300",
            "ce:indexed-name": "Javle M."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85116718584"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85116718584&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85116718584&origin=inward"
            }
        ],
        "source-id": "21100786228",
        "pii": "S2468125321001965",
        "citedby-count": "138",
        "prism:volume": "6",
        "subtype": "ar",
        "dc:title": "Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study",
        "openaccess": "0",
        "prism:issn": "24681253",
        "publishercopyright": "© 2021 Elsevier Ltd",
        "prism:issueIdentifier": "10",
        "subtypeDescription": "Article",
        "prism:publicationName": "The Lancet Gastroenterology and Hepatology",
        "prism:pageRange": "803-815",
        "prism:endingPage": "815",
        "openaccessFlag": "false",
        "prism:doi": "10.1016/S2468-1253(21)00196-5",
        "prism:startingPage": "803",
        "dc:identifier": "SCOPUS_ID:85116718584",
        "dc:publisher": "Elsevier Ltd"
    },
    "idxterms": {"mainterm": [
        {
            "$": "Administration, Oral",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Adult",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Aged",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Aged, 80 and over",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Alopecia",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Central Serous Chorioretinopathy",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Cholangiocarcinoma",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Deoxycytidine",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Disease Progression",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Dry Eye Syndromes",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Fatigue",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Female",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Hyperphosphatemia",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Male",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Middle Aged",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Neoplasm Metastasis",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Phenylurea Compounds",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Pyrimidines",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Radiation-Sensitizing Agents",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Receptor, Fibroblast Growth Factor, Type 1",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Receptor, Fibroblast Growth Factor, Type 2",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Retinal Detachment",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Safety",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Stomatitis",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Treatment Outcome",
            "@weight": "b",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": null,
    "subject-areas": {"subject-area": [
        {
            "@_fa": "true",
            "$": "Hepatology",
            "@code": "2721",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Gastroenterology",
            "@code": "2715",
            "@abbrev": "MEDI"
        }
    ]},
    "authors": {"author": [
        {
            "ce:given-name": "Milind",
            "preferred-name": {
                "ce:given-name": "Milind",
                "ce:initials": "M.",
                "ce:surname": "Javle",
                "ce:indexed-name": "Javle M."
            },
            "@seq": "1",
            "ce:initials": "M.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60015023",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015023"
            },
            "ce:degrees": "MD",
            "ce:surname": "Javle",
            "@auid": "35425978300",
            "author-url": "https://api.elsevier.com/content/author/author_id/35425978300",
            "ce:indexed-name": "Javle M."
        },
        {
            "ce:given-name": "Sameek",
            "preferred-name": {
                "ce:given-name": "Sameek",
                "ce:initials": "S.",
                "ce:surname": "Roychowdhury",
                "ce:indexed-name": "Roychowdhury S."
            },
            "@seq": "2",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60002058",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002058"
                },
                {
                    "@id": "60002058",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002058"
                }
            ],
            "ce:degrees": "MD",
            "ce:surname": "Roychowdhury",
            "@auid": "7005297383",
            "author-url": "https://api.elsevier.com/content/author/author_id/7005297383",
            "ce:indexed-name": "Roychowdhury S."
        },
        {
            "ce:given-name": "Robin Kate",
            "preferred-name": {
                "ce:given-name": "Robin Kate",
                "ce:initials": "R.K.",
                "ce:surname": "Kelley",
                "ce:indexed-name": "Kelley R.K."
            },
            "@seq": "3",
            "ce:initials": "R.K.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60029881",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029881"
            },
            "ce:degrees": "MD",
            "ce:surname": "Kelley",
            "@auid": "17635112900",
            "author-url": "https://api.elsevier.com/content/author/author_id/17635112900",
            "ce:indexed-name": "Kelley R.K."
        },
        {
            "ce:given-name": "Saeed",
            "preferred-name": {
                "ce:given-name": "Saeed",
                "ce:initials": "S.",
                "ce:surname": "Sadeghi",
                "ce:indexed-name": "Sadeghi S."
            },
            "@seq": "4",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60005247",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005247"
            },
            "ce:degrees": "MD",
            "ce:surname": "Sadeghi",
            "@auid": "7006682027",
            "author-url": "https://api.elsevier.com/content/author/author_id/7006682027",
            "ce:indexed-name": "Sadeghi S."
        },
        {
            "ce:given-name": "Teresa",
            "preferred-name": {
                "ce:given-name": "Teresa",
                "ce:initials": "T.",
                "ce:surname": "Macarulla",
                "ce:indexed-name": "Macarulla T."
            },
            "@seq": "5",
            "ce:initials": "T.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60012486",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012486"
            },
            "ce:degrees": "MD",
            "ce:surname": "Macarulla",
            "@auid": "8702260000",
            "author-url": "https://api.elsevier.com/content/author/author_id/8702260000",
            "ce:indexed-name": "Macarulla T."
        },
        {
            "ce:given-name": "Karl Heinz",
            "preferred-name": {
                "ce:given-name": "Karl Heinz",
                "ce:initials": "K.H.",
                "ce:surname": "Weiss",
                "ce:indexed-name": "Weiss K.H."
            },
            "@seq": "6",
            "ce:initials": "K.H.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60082880",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60082880"
                },
                {
                    "@id": "60003280",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60003280"
                }
            ],
            "ce:degrees": "MD",
            "ce:surname": "Weiss",
            "@auid": "13204330300",
            "author-url": "https://api.elsevier.com/content/author/author_id/13204330300",
            "ce:indexed-name": "Weiss K.H."
        },
        {
            "ce:given-name": "Dirk-Thomas",
            "preferred-name": {
                "ce:given-name": "Dirk Thomas",
                "ce:initials": "D.T.",
                "ce:surname": "Waldschmidt",
                "ce:indexed-name": "Waldschmidt D.T."
            },
            "@seq": "7",
            "ce:initials": "D.-T.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60008658",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008658"
            },
            "ce:degrees": "MD",
            "ce:surname": "Waldschmidt",
            "@auid": "6505951794",
            "author-url": "https://api.elsevier.com/content/author/author_id/6505951794",
            "ce:indexed-name": "Waldschmidt D.-T."
        },
        {
            "ce:given-name": "Lipika",
            "preferred-name": {
                "ce:given-name": "Lipika",
                "ce:initials": "L.",
                "ce:surname": "Goyal",
                "ce:indexed-name": "Goyal L."
            },
            "@seq": "8",
            "ce:initials": "L.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60008130",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008130"
            },
            "ce:degrees": "MD",
            "ce:surname": "Goyal",
            "@auid": "57216596420",
            "author-url": "https://api.elsevier.com/content/author/author_id/57216596420",
            "ce:indexed-name": "Goyal L."
        },
        {
            "ce:given-name": "Ivan",
            "preferred-name": {
                "ce:given-name": "Ivan",
                "ce:initials": "I.",
                "ce:surname": "Borbath",
                "ce:indexed-name": "Borbath I."
            },
            "@seq": "9",
            "ce:initials": "I.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60012936",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012936"
            },
            "ce:degrees": "MD",
            "ce:surname": "Borbath",
            "@auid": "8986695600",
            "author-url": "https://api.elsevier.com/content/author/author_id/8986695600",
            "ce:indexed-name": "Borbath I."
        },
        {
            "ce:given-name": "Anthony",
            "preferred-name": {
                "ce:given-name": "Anthony",
                "ce:initials": "A.",
                "ce:surname": "El-Khoueiry",
                "ce:indexed-name": "El-Khoueiry A."
            },
            "@seq": "10",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60022143",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022143"
            },
            "ce:degrees": "MD",
            "ce:surname": "El-Khoueiry",
            "@auid": "12244686400",
            "author-url": "https://api.elsevier.com/content/author/author_id/12244686400",
            "ce:indexed-name": "El-Khoueiry A."
        },
        {
            "ce:given-name": "Mitesh J",
            "preferred-name": {
                "ce:given-name": "Mitesh J.",
                "ce:initials": "M.J.",
                "ce:surname": "Borad",
                "ce:indexed-name": "Borad M.J."
            },
            "@seq": "11",
            "ce:initials": "M.J.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60026952",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026952"
            },
            "ce:degrees": "MD",
            "ce:surname": "Borad",
            "@auid": "57202377479",
            "author-url": "https://api.elsevier.com/content/author/author_id/57202377479",
            "ce:indexed-name": "Borad M.J."
        },
        {
            "ce:given-name": "Wei Peng",
            "preferred-name": {
                "ce:given-name": "Wei Peng",
                "ce:initials": "W.P.",
                "ce:surname": "Yong",
                "ce:indexed-name": "Yong W.P."
            },
            "@seq": "12",
            "ce:initials": "W.P.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60106366",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60106366"
                },
                {
                    "@id": "60106362",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60106362"
                }
            ],
            "ce:degrees": "MBChB",
            "ce:surname": "Yong",
            "@auid": "8928141300",
            "author-url": "https://api.elsevier.com/content/author/author_id/8928141300",
            "ce:indexed-name": "Yong W.P."
        },
        {
            "ce:given-name": "Philip A",
            "preferred-name": {
                "ce:given-name": "Philip A.",
                "ce:initials": "P.A.",
                "ce:surname": "Philip",
                "ce:indexed-name": "Philip P.A."
            },
            "@seq": "13",
            "ce:initials": "P.A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60033199",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60033199"
            },
            "ce:degrees": "MD",
            "ce:surname": "Philip",
            "@auid": "7102577497",
            "author-url": "https://api.elsevier.com/content/author/author_id/7102577497",
            "ce:indexed-name": "Philip P.A."
        },
        {
            "ce:given-name": "Michael",
            "preferred-name": {
                "ce:given-name": "Michael",
                "ce:initials": "M.",
                "ce:surname": "Bitzer",
                "ce:indexed-name": "Bitzer M."
            },
            "@seq": "14",
            "ce:initials": "M.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60017246",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017246"
                },
                {
                    "@id": "60017246",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017246"
                }
            ],
            "ce:degrees": "MD",
            "ce:surname": "Bitzer",
            "@auid": "57203106194",
            "author-url": "https://api.elsevier.com/content/author/author_id/57203106194",
            "ce:indexed-name": "Bitzer M."
        },
        {
            "ce:given-name": "Surbpong",
            "preferred-name": {
                "ce:given-name": "Surbpong",
                "ce:initials": "S.",
                "ce:surname": "Tanasanvimon",
                "ce:indexed-name": "Tanasanvimon S."
            },
            "@seq": "15",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60028190",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"
            },
            "ce:degrees": "MD",
            "ce:surname": "Tanasanvimon",
            "@auid": "23089332900",
            "author-url": "https://api.elsevier.com/content/author/author_id/23089332900",
            "ce:indexed-name": "Tanasanvimon S."
        },
        {
            "ce:given-name": "Ai",
            "preferred-name": {
                "ce:given-name": "Ai",
                "ce:initials": "A.",
                "ce:surname": "Li",
                "ce:indexed-name": "Li A."
            },
            "@seq": "16",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "122213671",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122213671"
            },
            "ce:degrees": "PhD",
            "ce:surname": "Li",
            "@auid": "57218602375",
            "author-url": "https://api.elsevier.com/content/author/author_id/57218602375",
            "ce:indexed-name": "Li A."
        },
        {
            "ce:given-name": "Amit",
            "preferred-name": {
                "ce:given-name": "Amit",
                "ce:initials": "A.",
                "ce:surname": "Pande",
                "ce:indexed-name": "Pande A."
            },
            "@seq": "17",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "100822091",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100822091"
            },
            "ce:degrees": "MD",
            "ce:surname": "Pande",
            "@auid": "57219673052",
            "author-url": "https://api.elsevier.com/content/author/author_id/57219673052",
            "ce:indexed-name": "Pande A."
        },
        {
            "ce:given-name": "Harris S",
            "preferred-name": {
                "ce:given-name": "Harris S.",
                "ce:initials": "H.S.",
                "ce:surname": "Soifer",
                "ce:indexed-name": "Soifer H.S."
            },
            "@seq": "18",
            "ce:initials": "H.S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "122213671",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122213671"
            },
            "ce:degrees": "PhD",
            "ce:surname": "Soifer",
            "@auid": "6508033211",
            "author-url": "https://api.elsevier.com/content/author/author_id/6508033211",
            "ce:indexed-name": "Soifer H.S."
        },
        {
            "ce:given-name": "Stacie Peacock",
            "preferred-name": {
                "ce:given-name": "Stacie Peacock",
                "ce:initials": "S.P.",
                "ce:surname": "Shepherd",
                "ce:indexed-name": "Shepherd S.P."
            },
            "@seq": "19",
            "ce:initials": "S.P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "100822091",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100822091"
            },
            "ce:degrees": "MD",
            "ce:surname": "Shepherd",
            "@auid": "57303434600",
            "author-url": "https://api.elsevier.com/content/author/author_id/57303434600",
            "ce:indexed-name": "Shepherd S.P."
        },
        {
            "ce:given-name": "Susan",
            "preferred-name": {
                "ce:given-name": "Susan",
                "ce:initials": "S.",
                "ce:surname": "Moran",
                "ce:indexed-name": "Moran S."
            },
            "@seq": "20",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "100822091",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100822091"
            },
            "ce:degrees": "MD",
            "ce:surname": "Moran",
            "@auid": "7102511953",
            "author-url": "https://api.elsevier.com/content/author/author_id/7102511953",
            "ce:indexed-name": "Moran S."
        },
        {
            "ce:given-name": "Andrew X",
            "preferred-name": {
                "ce:given-name": "Andrew X.",
                "ce:initials": "A.X.",
                "ce:surname": "Zhu",
                "ce:indexed-name": "Zhu A.X."
            },
            "@seq": "21",
            "ce:initials": "A.X.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60008130",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008130"
                },
                {
                    "@id": "60108904",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60108904"
                }
            ],
            "ce:degrees": "MD",
            "ce:surname": "Zhu",
            "@auid": "57216593782",
            "author-url": "https://api.elsevier.com/content/author/author_id/57216593782",
            "ce:indexed-name": "Zhu A.X."
        },
        {
            "ce:given-name": "Tanios S",
            "preferred-name": {
                "ce:given-name": "Tanios S.",
                "ce:initials": "T.S.",
                "ce:surname": "Bekaii-Saab",
                "ce:indexed-name": "Bekaii-Saab T.S."
            },
            "@seq": "22",
            "ce:initials": "T.S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60026952",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026952"
            },
            "ce:degrees": "MD",
            "ce:surname": "Bekaii-Saab",
            "@auid": "8643412400",
            "author-url": "https://api.elsevier.com/content/author/author_id/8643412400",
            "ce:indexed-name": "Bekaii-Saab T.S."
        },
        {
            "ce:given-name": "Ghassan K",
            "preferred-name": {
                "ce:given-name": "Ghassan K.",
                "ce:initials": "G.K.",
                "ce:surname": "Abou-Alfa",
                "ce:indexed-name": "Abou-Alfa G.K."
            },
            "@seq": "23",
            "ce:initials": "G.K.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60007997",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997"
                }
            ],
            "ce:degrees": "MD",
            "ce:surname": "Abou-Alfa",
            "@auid": "8660213800",
            "author-url": "https://api.elsevier.com/content/author/author_id/8660213800",
            "ce:indexed-name": "Abou-Alfa G.K."
        }
    ]}
}}